Olanzapine/samidorphan
| Combination of | |
|---|---|
| Olanzapine | Atypical antipsychotic |
| Samidorphan | Opioid antagonist |
| Clinical data | |
| Trade names | Lybalvi |
| Other names | ALKS-3831; OLZ/SAM |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a621051 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Olanzapine/samidorphan, sold under the brand name Lybalvi, is a
fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder.[1] It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist.[1][2][3] Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect.[4][5] The formulation was approved for medical use in the United States in May 2021.[1][6]
References
- ^ a b c d "Lybalvi- olanzapine and samidorphan l-malate tablet, film coated". DailyMed. 24 February 2022. Retrieved 1 May 2023.
- S2CID 205750190.
- PMID 28163559.
- PMID 34526769.
- S2CID 236215923.
- ^ "Drug Approval Package: Lybalvi". U.S. Food and Drug Administration (FDA). 26 June 2021. Retrieved 12 September 2021.